These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
    Author: Robak T, Błasinka-Morawiec M, Krykowski E, Kasznicki M, Płuzanska A, Potemski P, Hellmann A, Zaucha JM, Lewandowski K, Dmoszynska A, Hansz J, Komarnicki M, Konopka L, Durzynski T, Ceglarek B, Sikorska A, Kotlarek-Haus S, Mazur G, Urasinski I, Zdziarska B, Maj S, Kopec I, Skotnicki AB, Dwilewicz-Trojaczek J, Grieb P.
    Journal: Leuk Lymphoma; 1996 Aug; 22(5-6):509-14. PubMed ID: 8882965.
    Abstract:
    The purpose of our study was to determine the effectiveness of 2-CdA in 2-hour intravenous infusions in the treatment of B-CLL. One hundred and ten patients with B-CLL received 1 to 10 courses of 2-CdA (median 2.5) at a dosage of 0.12 mg/kg daily for 5 consecutive days. Eighteen of them were untreated and 92 relapsed or became refractory to previous therapeutic modalities. Complete remission (CR) was achieved in 8 (7.3%) and partial remission (PR) in 35 patients (31.8%) giving an overall response rate of 39.1%. In 3 patients, cross-resistance to fludarabine was noticed. Toxic effects of 2-CdA were more frequently observed in previously treated patients. Hemorrhagic complications due to drug-induced thrombocytopenia were noticed in 25 (22.7%) and severe infections including sepsis in 14 (12.7%) patients.
    [Abstract] [Full Text] [Related] [New Search]